Chemours (NYSE:CC - Get Free Report) announced its earnings results on Monday. The specialty chemicals company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.32 by $0.08, Briefing.com reports. Chemours had a return on equity of 33.21% and a net margin of 2.16%. The firm had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.44 billion. During the same quarter in the previous year, the company earned $0.64 earnings per share. The firm's quarterly revenue was up .9% compared to the same quarter last year.
Shares of CC stock traded down $0.18 on Tuesday, reaching $20.40. The stock had a trading volume of 785,578 shares, compared to its average volume of 1,568,914. The company has a quick ratio of 1.01, a current ratio of 1.89 and a debt-to-equity ratio of 5.45. The firm's 50-day moving average is $18.97 and its two-hundred day moving average is $22.19. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of 40.18 and a beta of 1.75. Chemours has a 12 month low of $15.10 and a 12 month high of $32.70.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 4.90%. Chemours's payout ratio is 200.00%.
A number of equities research analysts have commented on CC shares. The Goldman Sachs Group decreased their price objective on Chemours from $29.00 to $23.00 and set a "neutral" rating for the company in a research report on Tuesday, September 3rd. UBS Group lowered their price target on Chemours from $30.00 to $28.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. JPMorgan Chase & Co. decreased their target price on Chemours from $25.00 to $18.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 6th. Royal Bank of Canada cut their price target on shares of Chemours from $35.00 to $28.00 and set an "outperform" rating for the company in a research note on Friday, October 11th. Finally, BMO Capital Markets lifted their target price on shares of Chemours from $30.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, October 7th. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, Chemours has a consensus rating of "Hold" and an average price target of $25.25.
View Our Latest Report on CC
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.